immatics biotechnologies GmbH (NASDAQ:IMTXW) — Market Cap & Net Worth
Market Cap & Net Worth: immatics biotechnologies GmbH (IMTXW)
immatics biotechnologies GmbH (NASDAQ:IMTXW) has a market capitalization of $5.72 ($5.72) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31813 globally and #6312 in its home market, demonstrating a -96.59% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying immatics biotechnologies GmbH's stock price $0.00 by its total outstanding shares 9527 (9.53K). Review total liabilities of immatics biotechnologies GmbH to assess the company's total debt and financial obligations.
immatics biotechnologies GmbH Market Cap History: 2020 to 2025
immatics biotechnologies GmbH's market capitalization history from 2020 to 2025. Data shows change from $27.44K to $5.72 (-83.89% CAGR).
immatics biotechnologies GmbH Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how immatics biotechnologies GmbH's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
immatics biotechnologies GmbH's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.00x
immatics biotechnologies GmbH's market cap is 0.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $27.44K | $31.25 Million | -$229.35 Million | 0.00x | N/A |
| 2021 | $41.82K | $34.76 Million | -$95.06 Million | 0.00x | N/A |
| 2022 | $23.91K | $172.83 Million | $37.51 Million | 0.00x | 0.00x |
| 2023 | $27.82K | $54.00 Million | -$96.99 Million | 0.00x | N/A |
| 2024 | $2.40K | $155.84 Million | $15.22 Million | 0.00x | 0.00x |
Competitor Companies of IMTXW by Market Capitalization
Companies near immatics biotechnologies GmbH in the global market cap rankings as of June 18, 2026.
Key companies related to immatics biotechnologies GmbH by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
immatics biotechnologies GmbH Historical Marketcap From 2020 to 2025
Between 2020 and today, immatics biotechnologies GmbH's market cap moved from $27.44K to $ 5.72, with a yearly change of -83.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $5.72 | -99.76% |
| 2024 | $2.40K | -91.39% |
| 2023 | $27.82K | +16.33% |
| 2022 | $23.91K | -42.82% |
| 2021 | $41.82K | +52.43% |
| 2020 | $27.44K | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of immatics biotechnologies GmbH was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.72 USD |
| MoneyControl | $5.72 USD |
| MarketWatch | $5.72 USD |
| marketcap.company | $5.72 USD |
| Reuters | $5.72 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About immatics biotechnologies GmbH
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapie… Read more